Advanced Proteome Therapeutics Corporation (APTCF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Burnaby, BC, Canada. Der aktuelle CEO ist Benjamin Krantz.
APTCF hat IPO-Datum 2009-07-10, gelistet an der Other OTC, eine Marktkapitalisierung von $149.63K.
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.
